Join our nurses conference to help you better understand the patient experience from detection through to treatment of advanced disease, and include updates in the latest areas of research that are changing the way we treat melanoma. There will be a focus on detection of suspicious lesions to empower all nurses to confidently identify when a lesion requires further scrutiny.
TICKETS $75 | BOOK HERE
Start Time
8:30 am
Monday, June 25, 2018
Finish Time
4:30 pm
Sunday, November 25, 2018
Address
Reg Richardson Auditorium, Level 1, Melanoma Institute Australia, 40 Rocklands Rd, Wollstonecraft, NSW 2065
Not a member yet? Register now
Are you a member? Login now
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
Dr Bruna Gouveia
Dr Gouveia has no interests to declare.
Dr Thomas Pennington
Dr Pennington has no interests to declare.
Prof Georgina Long
Prof Long is a consultant advisor for Aduro Biotech Inc, Amgen Inc, Bristol-Myers Squibb, Highlight Therapeutics S.L., Mass-Array, Merck, MSD, Novartis, OncoSec Medical, Pierre Fabre, Roche, QBiotics, Skyline DX and Sandoz.
Michelle Davey
Michelle Davey has no interests to declare.
Dr Alex Varey
Dr Varey has received honoraria from Medtronic, Acelity and Synthes.
Prof John Thompson
Professor Thompson has received honoraria for Advisory Board participation from MSD Australia and Bristol-Myers Squibb Australia. He has also received honoraria and travel expenses from GlaxoSmithKline and Provectus Inc
Prof Andrew Spillane
Prof Spillane has acted as an advisor/consultant and received an honorarium from Stryker for a workshop in 2019.
Prof Richard Scolyer
Prof Richard Scolyer has acted as a consultant advisor and received honorarium from the following companies: MSD, GlaxoSmithKline Australia, Bristol-Myers Squibb, Novartis Pharmaceuticals Australia Pty Ltd, Myriad, NeraCare and Amgen.
A/Prof Robyn Saw
A/Prof Robyn Saw is on the advisory board for Novartis and MSD, and has received speaking honoraria from Bristol-Myers Squibb.
A/Prof Alexander Menzies
A/Prof Alexander Menzies has acted as a consultant advisor and received honorarium from the following companies: Bristol-Myers Squibb, MSD, Novartis, Roche and Pierre-Fabre.
Dr Linda Martin
Dr Martin has acted as a consultant with Bristol-Myers Squibb.
A/Prof Pascale Guitera
A/Prof Guitera has acted as a consultant advisor and received honorarium from the following companies: Metaoptima and Avene.
Prof Angela Hong
Prof Hong is an author for UptoDate and receives loyalty from the publication.
A/Prof Matteo Carlino
A/Prof Carlino has acted as a consultant advisor for the following companies: Bristol-Myers Squibb, MSD, Novartis, Amgen, Roche, Pierre Fabre, Ideaya, Sanofi, Merck Serono, Nektar and Eisai. He has also received honoraria from Bristol-Myers Squibb, Merck Sharpe Dohme and Novartis.
Dr Iris Bartula
None
A/Prof Matteo Carlino
A/Prof Carlino has acted as a consultant advisor for the following companies: Bristol-Myers Squibb, MSD, Novartis, Amgen, Roche, Pierre Fabre, Ideaya, Sanofi, Merck Serono, Nektar and Eisai. He has also received honoraria from Bristol-Myers Squibb, Merck Sharpe Dohme and Novartis.
Shahn Coburn
None
Prof Anne Cust
None
Prof Diona Damian
None
Michelle Davey
None
Jane Freeman
None
A/Prof Pascale Guitera
A/Prof Guitera has acted as a consultant advisor and received honorarium from the following companies: Metaoptima and Avene.
Prof Angela Hong
Prof Hong is an author for UptoDate and receives loyalty from the publication.
Prof Georgina Long
Prof Long is a consultant advisor to a number of pharmaceutical or biotech companies developing drugs for cancer including Aduro Biotech Inc, Pierre-Fabre Medicament, Bristol-Myers Squibb Australia, Amgen Inc, MSD (Australia), MSD, Novartis Pharma AG and Array Biopharma.
Dr Linda Martin
Dr Martin has acted as a consultant with Bristol-Myers Squibb.
A/Prof Alexander Menzies
A/Prof Alexander Menzies has acted as a consultant advisor and received honorarium from the following companies: Bristol-Myers Squibb, MSD, Novartis, Roche and Pierre-Fabre.
Natalie Osborne
None
Dr Robert Rawson
None
A/Prof Robyn Saw
A/Prof Robyn Saw is on the advisory board for Novartis and MSD, and has received speaking honoraria from Bristol-Myers Squibb.
Prof Richard Scolyer
Prof Richard Scolyer has acted as a consultant advisor and received honorarium from the following companies: MSD, GlaxoSmithKline Australia, Bristol-Myers Squibb, Novartis Pharmaceuticals Australia Pty Ltd, Myriad, NeraCare and Amgen.
Dr Brindha Shivalingam
None
Dr Annika Smith
None
Prof Andrew Spillane
Prof Spillane has acted as an advisor/consultant and received an honorarium from Stryker for a workshop in 2019.
A/Prof Jonathan Stretch
None
Prof John Thompson
Professor Thompson has received honoraria for Advisory Board participation from MSD Australia and Bristol-Myers Squibb Australia. He has also received honoraria and travel expenses from GlaxoSmithKline and Provectus Inc.
Dr Alex Varey
Dr Varey has received honoraria from Medtronic, Acelity and Synthes.